Inclusion Criteria:

          -  Prior diagnosis of NB or ganglioneuroblastoma either by histologic verification and/or
             demonstration of tumor cells in the bone marrow with increased catecholamine levels.

          -  Male or female subjects ≤ 26 years of age

          -  Diagnosis of high risk NB at initial diagnosis or if non-high risk at time of initial
             diagnosis must have had evidence of metastatic progression when > 18 months of age.

          -  Measurable or evaluable disease

          -  Lansky or Karnofsky performance status score of ≥ 50

          -  Life expectancy of ≥ 8 weeks.

          -  Recovered from significant acute toxic effects of all prior chemotherapy,
             immunotherapy, or radiotherapy prior to enrollment onto this study.

          -  ≥ 7 days since last chemotherapy or biologic therapy administration

          -  No systemic corticosteroids (unless physiologic replacement dosing) within 7 days of
             enrollment. Topical Administration (e.g. inhaled or dermatologic) is allowed.

          -  ≥ 3 half-lives or 30 days from time of last dose of anti-tumor directed antibody
             therapy, whichever is shorter from time of enrollment

          -  ≥ 6 weeks from myeloablative therapy and autologous stem cell transplant (timed from
             stem cell infusion). Patients who received stem cell infusion following
             non-myelo-ablative therapy are eligible once they meet all other eligibility
             requirements. Patient must NOT have received a prior allogeneic hematopoietic stem
             cell transplant.

          -  No prior genetically modified cell therapy that is still detectable.

          -  Must not be receiving external beam radiation therapy at the time of study enrollment.
             ≥ 12 weeks from prior I131 MIBG therapy.

          -  Adequate organ function

          -  Adequate laboratory values

          -  Negative HIV antigen and antibody, Hepatitis B surface antigen and Hepatitis C
             antibody within 3 months prior to enrollment. For patients with positive Hepatitis C
             Ab, negative PCR testing must be documented in order to be eligible.

        Exclusion Criteria:

          -  History of relevant CNS pathology or current relevant CNS pathology (non-febrile
             seizure disorder requiring ongoing anti-epileptic medications, paresis, aphasia,
             cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, cerebellar
             disease, organic brain syndrome, psychosis, coordination or movement disorder).
             Patients may have CNS intracranial tumor.

          -  Pregnant or breast-feeding

          -  Unable to tolerate apheresis procedure including placement of temporary apheresis
             catheter if necessary

          -  Presence of active malignancy other than NB

          -  Presence of known intracranial metastatic neuroblastoma. Skull based disease with soft
             tissue extension is allowed.

          -  Presence of active severe infection

          -  Presence of any concurrent medical condition that, in the opinion of the protocol PI
             or designee, would prevent the patient from undergoing protocol-based therapy.

          -  Presence of a primary immunodeficiency/bone marrow failure syndrome

          -  Receiving any other anti-cancer agents or radiotherapy at the time of study entry

          -  Unwilling or unable to provide consent/assent for participation in the study and
             15-year follow-up